Comparison of Anti-Androgen Drugs in Female Hair Loss
The most common type of female hair loss is androgenetic alopecia (AGA), also known as seborrheic alopecia. Its core mechanism involves increased sensitivity of hair follicles to androgens (primarily dihydrotestosterone, DHT), leading to follicular miniaturization and a shortened growth phase. Anti-androgen drugs delay or improve this process by reducing androgen levels in the body or blocking their binding to receptors.
Currently, the anti-androgen drugs commonly used in clinical practice include spironolactone, cyproterone acetate, finasteride, and certain oral contraceptives. Their mechanisms of action, efficacy, and side effects vary, and selection should be based on the individual patient’s circumstances.
Spironolactone (Aldactone) is an aldosterone receptor antagonist with weak anti-androgenic effects. It works by inhibiting androgen production in the adrenal glands and ovaries and competitively blocking androgen receptors. Multiple studies have shown that spironolactone at doses of 50–200 mg per day can significantly reduce hair loss and improve hair density in women, particularly those with PCOS (polycystic ovary syndrome) or elevated androgen levels. Common side effects include menstrual irregularities, breast tenderness, dizziness, and hyperkalemia. It should be avoided in patients with renal impairment.
Cyproterone acetate is a potent progestogen with anti-androgenic activity, often used in combination with estrogen (e.g., in oral contraceptives like Diane-35). It suppresses gonadotropin secretion, reduces ovarian androgen production, and directly blocks androgen receptors in hair follicles. Clinical evidence indicates that cyproterone acetate can improve female androgenetic alopecia, especially in women with concurrent acne or hirsutism. Side effects include mood swings, weight gain, and an increased risk of thrombosis (higher in smokers or obese individuals); liver function should be monitored regularly.
Finasteride is a 5α-reductase inhibitor that blocks the conversion of testosterone to DHT, reducing DHT levels in the serum and scalp. Although finasteride is widely used for male hair loss, it has not been officially approved for use in women. Some small studies, particularly in postmenopausal women, have shown that finasteride at doses of 1.25–2.5 mg per day can improve hair loss. In premenopausal women, strict contraception is required due to the risk of teratogenicity. Side effects include decreased libido, depressed mood, and breast tenderness, with a lower incidence than in men. It is important to emphasize that the evidence for finasteride in women remains insufficient, and a thorough evaluation is necessary before use.
Certain progestins in oral contraceptives (OCPs)—such as drospirenone, cyproterone acetate, and norgestimate—possess anti-androgenic activity. By suppressing ovulation and ovarian androgen secretion, they indirectly lower androgen levels. OCPs are primarily indicated for women who require contraception, have irregular menstrual cycles, or exhibit symptoms of androgen excess. Studies suggest that OCPs containing anti-androgenic progestins offer some improvement in mild to moderate female hair loss, though their efficacy is less pronounced than that of spironolactone or cyproterone acetate used alone. Side effects include thrombosis risk, weight changes, and mood disturbances.
Comparing these drugs, spironolactone and cyproterone acetate have the strongest evidence of efficacy, each with a specific focus: spironolactone is more commonly used in women without contraceptive needs, while cyproterone acetate is often combined with estrogen. Finasteride serves as a second-line option, primarily considered for postmenopausal women or those intolerant to the aforementioned drugs. Oral contraceptives are suitable for women with additional symptoms. Furthermore, topical minoxidil is the FDA-approved first-line treatment for female hair loss and can be used in combination with these anti-androgen drugs to enhance effects.
Special caution is required: All anti-androgen drugs must be used under medical supervision due to significant individual variability, and regular monitoring of serum potassium, liver and kidney function, and coagulation parameters is necessary. Premenopausal women using these drugs must practice strict contraception (especially with finasteride and cyproterone acetate). Efficacy typically becomes apparent after 6–12 months of use, though a minority may show no improvement. If blurred vision, difficulty breathing, or severe headache occur after taking the medication, seek immediate medical attention.
In summary, anti-androgen drugs are important tools in treating female androgenetic alopecia, but they are not a panacea. The choice of drug and combination depends on specific hormone levels, reproductive status, accompanying symptoms, and patient tolerance. Evidence-based medicine emphasizes individualized treatment; it is recommended to develop a plan under the evaluation of a dermatologist or endocrinologist.
For reference only, not medical advice.